CLEC-1 on human DCs dampens DC activation and restrains downstream Th17 responses.166 CLEC-1-deficient mice eradicate colorectal tumors by combining with cytotoxic and immunogenic chemotherapy, and CLEC-1 blocking antibodies augment the phagocytosis of CLEC-1 L-positive tumor cells by DCs and macrophages.167 CLEC-1 probably signifies a new therapeutic agent to regulate the immune response in transplantation, autoimmunity, and cancer. This evidence concerns the gene CLEC1A and neoplasm.